TriangleNCT01496118 · OUTCOME
Overall-survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- up to 6 years
What was measured
Measured from time of first study treatment until date of death or date last known alive.
Analysis population: All patients receiving dose level 4 and dose level 6 doses (both escalation and expansion phases combined) who had a post-baseline disease assessment per protocol were included in the analysis. 3 patients in dose level 4 and 1 patient in dose level 6 did not have a post-baseline assessment and were excluded from analysis.
Groups in this outcome
Dose Level 4 - Escalation and Expansion
Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 45 mg/m\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 45 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 30 mg D 1, 3, 5, 15, 17, 19
Dose Level 6 - Escalation and Expansion
Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 56 mg/m\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 56 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19
| Group | Source count |
|---|---|
| Dose Level 4 - Escalation and Expansion | 31 |
| Dose Level 6 - Escalation and Expansion | 32 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dose Level 4 - Escalation and Expansion | 29.2 | Not reported | 22 | 50.4 | Not reported |
| Dose Level 6 - Escalation and Expansion | 44.6 | Not reported | 20.8 | NA | Upper confidence limit is not estimable by Kaplan Meier method due to insufficient observed events |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 22
- upper Limit
- 50.4
- value
- 29.2
- comment
- Upper confidence limit is not estimable by Kaplan Meier method due to insufficient observed events
- group Id
- OG001
- lower Limit
- 20.8
- upper Limit
- NA
- value
- 44.6
- denoms
- counts
- group Id
- OG000
- value
- 31
- group Id
- OG001
- value
- 32
- units
- Participants
- description
- Measured from time of first study treatment until date of death or date last known alive.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 45 mg/m\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 45 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 30 mg D 1, 3, 5, 15, 17, 19
- id
- OG000
- title
- Dose Level 4 - Escalation and Expansion
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 56 mg/m\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 56 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19
- id
- OG001
- title
- Dose Level 6 - Escalation and Expansion
- param Type
- MEDIAN
- population Description
- All patients receiving dose level 4 and dose level 6 doses (both escalation and expansion phases combined) who had a post-baseline disease assessment per protocol were included in the analysis. 3 patients in dose level 4 and 1 patient in dose level 6 did not have a post-baseline assessment and were excluded from analysis.
- reporting Status
- POSTED
- time Frame
- up to 6 years
- title
- Overall-survival (OS)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice